Bladder preservation with chemotherapy, immunotherapy, and radiation for bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of bladder cancer called 'muscle-invasive' (cancer that has grown into the muscle layer), but it must not have spread to lymph nodes or other organs.
- You must have the most common type of bladder cancer called 'transitional cell carcinoma' (also known as urothelial carcinoma).
- You must be in good health overall, with a performance status of 0 or 1 (able to carry on normal activities).
- You must have adequate kidney, liver, and blood cell counts as shown by blood tests.
- You must not have had prior chemotherapy, radiation, or certain other treatments for your bladder cancer.
- You must not have a weakened immune system or active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three standard treatments for muscle-invasive bladder cancer: bladder removal surgery, radiation combined with chemotherapy, or both. It aims to find which approach works best while preserving quality of life.
This study looks at how chemotherapy given before bladder removal surgery changes the immune environment around the tumor. The goal is to see if these changes can help predict how well the treatment works, which could lead to better personalized care.
This study tests a new immunotherapy drug called sasanlimab as a maintenance treatment after chemotherapy and bladder removal surgery. The goal is to see if it helps keep the cancer from coming back in people with muscle-invasive bladder cancer.
This trial tests a new treatment approach using MRI to guide bladder preservation for patients with muscle-invasive bladder cancer. The goal is to treat the cancer with chemotherapy and radiation instead of removing the bladder, potentially allowing you to keep your bladder while fighting the cancer.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.